Achmea Investment Management B.V. Trims Holdings in Thermo Fisher Scientific Inc. (TMO)

Achmea Investment Management B.V. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,400 shares of the medical research company’s stock after selling 2,013 shares during the quarter. Achmea Investment Management B.V.’s holdings in Thermo Fisher Scientific were worth $4,977,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new stake in Thermo Fisher Scientific in the second quarter worth $103,000. Horrell Capital Management Inc. acquired a new stake in Thermo Fisher Scientific in the second quarter worth $104,000. Edge Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 8,077.8% in the second quarter. Edge Wealth Management LLC now owns 736 shares of the medical research company’s stock worth $152,000 after purchasing an additional 727 shares during the period. Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific in the second quarter worth $154,000. Finally, Summit Financial Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $201,000. Institutional investors and hedge funds own 85.22% of the company’s stock.

Shares of NYSE TMO opened at $243.45 on Friday. The stock has a market cap of $98.84 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.78 and a beta of 1.08. Thermo Fisher Scientific Inc. has a 1 year low of $181.51 and a 1 year high of $249.95. The company has a quick ratio of 1.27, a current ratio of 1.84 and a debt-to-equity ratio of 0.66.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $2.55 by $0.07. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The company had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.70 billion. During the same period last year, the firm earned $2.31 earnings per share. The firm’s revenue was up 15.7% on a year-over-year basis. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 11.04 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a share repurchase plan on Friday, September 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2.1% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, January 15th. Investors of record on Monday, December 17th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend is Friday, December 14th. Thermo Fisher Scientific’s payout ratio is currently 7.17%.

In related news, CEO Marc N. Casper sold 125,520 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $247.50, for a total transaction of $31,066,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.49% of the stock is owned by company insiders.

A number of research analysts have recently issued reports on TMO shares. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $274.00 price objective for the company in a report on Monday, October 1st. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $250.00 to $275.00 and gave the company an “overweight” rating in a report on Monday, September 24th. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $233.00 to $242.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. Citigroup lifted their price objective on shares of Thermo Fisher Scientific from $260.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, October 10th. Finally, Cleveland Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Thursday, October 18th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average target price of $261.45.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.wkrb13.com/2018/11/11/achmea-investment-management-b-v-trims-holdings-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Find a Trading Strategy That Works

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply